The earnings call highlighted strong financial performance and growth in the HIV business, along with successful M&A activities and advancements in drug development. These positives were tempered by declines in domestic and overseas sales, particularly in China, and concerns regarding R&D cost management. Despite these challenges, the overall outlook remains optimistic due to strategic growth initiatives.

Company Guidance

During the first quarter financial results briefing for fiscal year 2025, SHIONOGI reported significant growth in both financial and non-financial metrics. The company achieved a year-over-year increase in revenue to JPY99.8 billion, up by JPY2.2 billion, with operating profit reaching JPY35.1 billion, an increase of JPY7 billion. Profit before tax rose to JPY46.3 billion, up by JPY9.8 billion, and profit attributable to owners of the parent increased by JPY8.7 billion to JPY39.4 billion. EBITDA also saw a rise to JPY40.6 billion, marking a JPY7 billion increase. Significant contributors to this growth included the strong performance of the HIV business, with revenue from this segment driven by ViiV's HIV franchise and royalty income from Roche's Xofluza, which benefited from a flu epidemic in China and the U.S. Non-financial milestones included the completion of a tender offer for Torii Pharmaceutical and progress towards an M&A with the JT Group's pharmaceutical business. The company's strategic focus on pipeline developments, including the filing of Ensitrelvir in Europe and the U.S., is expected to support medium- to long-term growth.

Strong Financial Performance

Revenue for Q1 FY2025 increased to JPY99.8 billion, a rise of JPY2.2 billion compared to the same period last year. Operating profit increased by JPY7 billion to JPY35.1 billion, and profit before tax rose by JPY9.8 billion to JPY46.3 billion. Profit attributable to owners of the parent was JPY39.4 billion, an increase of JPY8.7 billion.

HIV Business Growth

The HIV business showed strong growth, with ViiV's HIV franchise contributing to higher royalty income. Long-acting formulations like Cabenuva and Dovato are driving this growth.

Advancements in Drug Development

Significant progress in the development pipelines, including the filing of Ensitrelvir in Europe and the US. The development of S-365598, a third-generation integrase inhibitor, is ongoing with promising antiviral activity.

Successful M&A Activity

Completion of the tender offer for Torii Pharmaceutical and progress towards merging with the JT Group pharmaceutical business.

Shionogi & Co (SGIOF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SGIOF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 27, 2025	2025 (Q2)	0.33 / -	0.419	―	―	―
Jul 28, 2025	2025 (Q1)	0.28 / 0.31	0.244	28.42% (+0.07)		―
May 12, 2025	2024 (Q4)	0.33 / 0.29	0.277	5.35% (+0.01)		―
Jan 31, 2025	2024 (Q3)	0.31 / 0.40	0.288	40.43% (+0.12)		―
Oct 28, 2024	2024 (Q2)	0.32 / 0.42	0.371	12.88% (+0.05)		―
Jul 29, 2024	2024 (Q1)	0.27 / 0.24	0.327	-25.27% (-0.08)		―
May 13, 2024	2023 (Q4)	0.29 / 0.28	0.164	69.16% (+0.11)		―
Jan 31, 2024	2023 (Q3)	0.44 / 0.29	0.764	-62.31% (-0.48)		―
Oct 31, 2023	2023 (Q2)	0.27 / 0.37	0.17	118.59% (+0.20)		―
Jul 31, 2023	2023 (Q1)	0.34 / 0.33	0.261	25.57% (+0.07)		―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SGIOF Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 28, 2025	$16.81	$17.60	+4.70%
May 12, 2025	$15.20	$15.20	0.00%
Jan 31, 2025	$14.62	$15.40	+5.34%
Oct 28, 2024	$13.55	$13.61	+0.44%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Shionogi & Co Ltd (SGIOF) report earnings?

Shionogi & Co Ltd (SGIOF) is schdueled to report earning on Oct 27, 2025, TBA (Confirmed).

What is Shionogi & Co Ltd (SGIOF) earnings time?

Shionogi & Co Ltd (SGIOF) earnings time is at Oct 27, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SGIOF EPS forecast?

SGIOF EPS forecast for the fiscal quarter 2025 (Q2) is 0.33.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing